Upper limb impairment is common in primary progressive multiple sclerosis (PPMS). A recent study, titled ORATORIO, examined the effects of ocrelizumab on confirmed progression and confirmed improvement in upper limb impairment in patients.
Patients with PPMS received ocrelizumab 600mg or placebo every 24 weeks for 120 weeks or more. The Nine-Hole Peg Test (9HPT) was used at the beginning and every 12 weeks thereafter to measure hand function. Both hands were tested twice, the dominant hand first. Researchers analysed specific goals, which included changes in the time needed to finish the 9HPT, and the proportion of patients with confirmed progression of 20% or greater in this peg test — the usual threshold for clinically meaningful change in this test.
Patients treated with ocrelizumab saw a significantly reduced change in their 9HPT time over 120 weeks, as well as a reduction in the risk of confirmed progression of 20% or greater in 9HPT time for both hands and the risk of more severe 9HPT progression versus placebo.
The researchers concluded that Ocrelizumab reduces the risk of upper limb disability progression and may increase the possibility of improvement versus placebo in PPMS.
Source: MS-UK 19/11/2018